Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessing the MGMT status in glioblastoma: one step forward, two steps back?

Literature DB >> 23430603

Assessing the MGMT status in glioblastoma: one step forward, two steps back?

Michael Weller.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 23430603 PMCID： PMC3578498 DOI： 10.1093/neuonc/not014

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

9 in total

1. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors: Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal: Lancet Oncol Date: 2012-08-08 Impact factor: 41.316

Review 2. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors: Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal: Nat Rev Neurol Date: 2009-12-08 Impact factor: 42.937

3. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245

4. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors: Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300

Review 5. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors: Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300

6. MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245

7. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

Authors: Matthias Preusser; Robert Charles Janzer; Jörg Felsberg; Guido Reifenberger; Marie-France Hamou; Annie-Claire Diserens; Roger Stupp; Thierry Gorlia; Christine Marosi; Harald Heinzl; Johannes A Hainfellner; Monika Hegi
Journal: Brain Pathol Date: 2008-04-08 Impact factor: 6.508

8. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Authors: K A Jaeckle; H J Eyre; J J Townsend; S Schulman; H M Knudson; M Belanich; D B Yarosh; S I Bearman; D J Giroux; S C Schold
Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544

9. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors: Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal: Lancet Oncol Date: 2012-05-10 Impact factor: 41.316